News & Analysis » US

Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro And Aspart With RHuPH20

(RTTNews) - Halozyme Therapeutics Inc. (HALO) said it has initiated two phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme in combination with the two leading commercially available mealtime analogs including insulin aspart, the active ingredient in NovoLog, and insulin lispro, the active ingredient in Humalog.

Diabetes patients enrolled in these cross-over design studies will receive an insulin analog alone and the Analog-PH20 treatment for 12 weeks each.

Each study will enroll about 110 patients and begins with a 4 to 6 week titration period where patients optimize their basal insulin dosing.

The primary endpoint of each study will be a comparison of glycemic control, as assessed by the change in A1C from baseline.